Epigenetics and cancer

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 57-65

  Baylin, Stephen B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751487759     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10005-6     Document Type: Chapter

References (94)

1. Epigenetics 2006, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Kornberg RD, Lorch Y Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98:285.
3. Aalfs JD, Kingston RE What does 'chromatin remodeling' mean?. Trends Biochem Sci 2000, 25:548.
4. Li H, Ilin S, Wang W, et al. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 2006, 442:91.
5. Kingston R, Tamkun JW Transcriptional regulation by trithorax group. Epigenetics 2006, 231. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. C.D. Allis, T. Jenuwein, D. Reinberd (Eds.).
6. Bird A DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6.
7. Bird AP, Wolffe AP Methylation-induced repression-belts, braces, and chromatin. Cell 1999, 99:451.
8. Jenuwein T The epigenetic magic of histone lysine methylation. Febs J 2006, 273:3121.
9. Jenuwein T, Allis CD Translating the histone code. Science 2001, 293:1074.
10. Kouzarides T Histone methylation in transcriptional control. Curr Opin Genet Dev 2002, 12:198.
11. Kubicek S, Schotta G, Lachner M, et al. The role of histone modifications in epigenetic transitions during normal and perturbed development. Ernst Schering Res Found Workshop 2006, 1.
12. Lachner M, Jenuwein T The many faces of histone lysine methylation. Curr Opin Cell Biol 2002, 14:286.
13. Forneris F, Binda C, Vanoni MA, Mattevi A, Battaglioli E Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett 2005, 579:2203.
14. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811.
15. Yamane K, Toumazou C, Tsukada Y, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006, 125:483.
16. Bestor TH The host defence function of genomic methylation patterns. Novartis Found Symp 1998, 214:187.
17. Bird AP CpG-rich islands and the function of DNA methylation. [Review]. Nature 1986, 321:209.
18. Brockdorff N, Turner BM Doaeage compensation in mammals. Epigenetics 2006, 321. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. C.D. Allis, T. Jenuwein, D. Reinberd (Eds.).
19. Bartolomei MS Epigenetics: role of germ cell imprinting. Adv Exp Med Biol 2003, 518:239.
20. Ferguson-Smith AC, Surani MA Imprinting and the epigenetic asymmetry between parental genomes. Science 2001, 293:1086.
21. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 2001, 293:2453.
22. Yisraeli J, Frank D, Razin A, Cedar H Effect of in vitro DNA methylation on beta-globin gene expression. Proc Natl Acad Sci U S A 1988, 85:4638.
23. Tamaru H, Selker EU Synthesis of signals for de novo DNA methylation in Neurospora crassa. Mol Cell Biol 2003, 23:2379.
24. Jackson JP, Johnson L, Jasencakova Z, et al. Dimethylation of histone H3 lysine 9 is a critical mark for DNA methylation and gene silencing in Arabidopsis thaliana. Chromosoma 2004, 112:308.
25. Jones PA, Baylin SB The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415.
26. Jones PA, Laird PW Cancer epigenetics comes of age. Nat Genet 1999, 21:163.
27. Feinberg AP The epigenetics of cancer etiology. Semin Cancer Biol 2004, 14:427.
28. Okano M, Bell DW, Haber DA, Li E DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247.
29. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999, 402:187.
30. Baylin SB, Jones PA Epigenetic determinants of cancer. Epigenetics 2006, 457. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. C.D. Allis, T. Jenuwein, D. Reinberg (Eds.).
31. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002, 31:141.
32. Baylin SB, Ohm JE Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107.
33. Ushijima T Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5:223.
34. Johnson L, Cao X, Jacobsen S Interplay between two epigenetic marks: DNA methylation and histone H3 lysine 9 methylation. Curr Biol 2002, 12:1360.
35. Ringrose L, Paro R Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins. Annu Rev Genet 2004, 38:413.
36. Fujimura Y, Isono K, Vidal M, et al. Distinct roles of polycomb group gene products in transcriptionally repressed and active domains of Hoxb8. Development 2006, 133:2371.
37. Grossniklaus U, Paro R Transciptional silencing by polycomb group. Epigenetics 2006, 211. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. C.D. Allis, T. Jenuwein, D. Reinberg (Eds.).
38. Rountree MR, Bachman KE, Baylin SB DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000, 25:269.
39. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP DNMT1 forms a complex with rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000, 25:338.
40. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000, 24:88.
41. Ting AH, McGarvey KM, Baylin SB The cancer epigenome: components and functional correlates. Genes Dev 2006, 20:3215.
42. Kirmizis A, Bartley SM, Farnham PJ Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003, 2:113.
43. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606.
44. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624.
45. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391.
46. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006, 66:3541.
47. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157.
48. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2006, 39:232.
49. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor cancer genes to DNA hypermethylation and heritable silencing. Nature Gene 2007, In press, 2007.
50. Feinberg AP, Ohlsson R, Henikoff S The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7:21.
51. Sherr CJ Cancer cell cycles. Science 1996, 274:1672.
52. Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16(INK4a). Nature 2006, 443:421.
53. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453.
54. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16(INK4a) expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448.
55. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998, 95:11891.
56. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525.
57. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61:8284.
58. Holst CR, Nuovo GJ, Esteller M, et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003, 63:1596.
59. Foster SA, Wong DJ, Barrett MT, Galloway DA Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998, 18:1793.
60. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84.
61. Reynolds PA, Sigaroudinia M, Zardo G, et al. Tumor suppressor P16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem 2006, 281:24790.
62. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994, 54:5523.
63. Siu IM, Robinson DR, Schwartz S, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res 1999, 59:63.
64. Kinzler KW, Vogelstein B Cancer-susceptibility genes: gatekeepers and caretakers. Nature 1997, 386:761.
65. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784.
66. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004, 36:417.
67. Rattner A, Hsieh JC, Smallwood PM, et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA 1997, 94:2859.
68. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262.
69. Cao R, Zhang Y SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004, 15:57.
70. Egger G, Liang G, Aparicio A, Jones PA Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457.
71. Herman JG, Baylin SB Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042.
72. Belinsky SA Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004, 4:707.
73. Laird PW The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253.
74. Esteller M, Corn PG, Baylin SB, Herman JG A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225.
75. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821.
76. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006, 66:3338.
77. Machida EO, Brock MV, Hooker CM, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006, 66:6210.
78. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006, 12:7329.
79. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001, 93:1747.
80. Issa JP CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 2000, 249:101.
81. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350.
82. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997.
83. Yoo CB, Jones PA Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37.
84. Marks PA, Richon VM, Miller T, Kelly WK Histone deacetylase inhibitors. Adv Cancer Res 2004, 91:137.
85. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361.
86. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase I/II study of the combination of 5. Blood 2006, 108:3271.
87. Issa JP Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005, 2(Suppl 1):S24.
88. Issa JP DNA methylation in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 2005, 3:684.
89. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441.
90. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429.
91. Gaymes TJ, Padua RA, Pla M, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Mol Cancer Res 2006, 4:563.
92. Jackson-Grusby L, Laird PW, et al. Mutagenicity of 5-aza-2?deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 1997, 94:4681.
93. Liang G, Chan MF, Tomigahara Y, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002, 22:480.
94. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006, 2:344.